A drug used alone to treat hepatocellular carcinoma (a type of liver cancer) in certain patients who have already been treated with sorafenib. It is also used with other drugs to treat colorectal cancer and non-small cell lung cancer that have spread to other parts of the body and have gotten worse during or after treatment with other anticancer drugs. It is also used alone or with another drug to treat cancer of the stomach or gastroesophageal junction (the area where the esophagus connects to the stomach) that is advanced or has spread to other parts of the body and has gotten worse during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Ramucirumab binds to receptors for a protein called vascular endothelial growth factor, which may be found on some types of cancer cells. This may prevent the growth of new blood vessels that tumors need to grow. Ramucirumab is a type of antiangiogenesis agent and a type of monoclonal antibody. Also called anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Cyramza, and IMC-1121B.